TEVA DEADLINE ALERT
Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Teva To Contact Him Directly To Discuss Their Options
If you suffered losses exceeding $50,000 investing in Teva stock or options between October 29, 2015 and August 18, 2020 and would like to discuss your legal rights, please fill out the form below. You can also call Faruqi & Faruqi partner James Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
There is no cost or obligation to you.
Faruqi & Faruqi, LLP, a leading minority and certified woman-owned national securities law firm, is investigating claims against Teva Pharmaceutical Industries Limited (“Teva” or the “Company”) (NYSE:TEVA) and reminds investors of the November 23, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
As detailed below, the lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Teva had made substantial illegal kickback payments to charitable foundations to cover Medicare co-payment obligations of patients taking Copaxone; (2) accordingly, Teva’s revenues derived from Copaxone were in part the product of unlawful conduct and thus unsustainable; (3) the foregoing misconduct subjected Teva to a foreseeable risk of heightened regulatory scrutiny and enforcement, as well as reputational harm, when the truth became known; and (4) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Specifically, on August 18, 2020, the United States Department of Justice (“DOJ”) issued a press release announcing that it had filed a complaint against Teva under the False Claims Act. Specifically, “[t]he government alleges that, from 2007 through 2015, Teva paid The Assistance Fund (TAF) and Chronic Disease Fund (CDF) with the intent and understanding that the foundations would use Teva’s money to cover the Medicare co-pays of patients taking Copaxone. During the same period, Teva raised the price of Copaxone from approximately $17,000 per year to over $73,000 per year.”
On this news, Teva’s American depositary receipt (“ADR”) price fell $1.11 per ADR from its previous close on August 17, 2020, or 9.6%, to close at $10.48 per ADR on August 18, 2020, on unusually heavy trading volume.
Teva Pharmaceutical Industries Limited
* The submission of this form does not create an attorney-client relationship.
Filed on 09/23/2020
Class period 10/29/2015 - 08/18/2020
Lead Plaintiff Deadline 11/23/2020
685 Third Avenue 26th Floor
10017 New York, New York
Phone (212) 983-9330
Fax (212) 983-9331
Robert W. Killorin firstname.lastname@example.org Phone (404) 847-0617 Fax (404) 506-9534
James M. Wilson, Jr. email@example.com Phone (212) 983-9330 Fax (212) 983-9331